| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Licoisoflavone A targets the cell cycle, inhibiting proliferation and causing G1/S phase arrest in cancer cells. It also induces apoptosis. It is a potential inhibitor of the multidrug resistance protein (MRP). It inhibits lipid peroxidation.
|
|---|---|
| ln Vitro |
In vitro, Licoisoflavone A inhibits proliferation, induces apoptosis, and causes G1/S phase arrest in colorectal cancer (CRC) cells. It inhibits lipid peroxidation with an IC₅₀ of 7.2 μM. It has anti-inflammatory and antioxidant activities.
|
| ln Vivo |
In vivo, Licoisoflavone A is orally active. Its anti-proliferative and pro-apoptotic activities suggest potential for cancer therapy, particularly for colorectal cancer. However, specific in vivo data are limited.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for Licoisoflavone A involve measuring its inhibition of lipid peroxidation using a model system, such as linoleic acid oxidation, and monitoring the formation of conjugated dienes or malondialdehyde (MDA). Its inhibition of MRP can be measured using membrane vesicles and a fluorescent substrate.
|
| Cell Assay |
In vitro cell-based assays for Licoisoflavone A use colorectal cancer cell lines (e.g., HCT116, HT29). Cells are treated with the compound, and cell proliferation is assessed using MTT or colony formation assays. Cell cycle analysis is performed by flow cytometry, and apoptosis is confirmed by Annexin V/PI staining.
|
| Animal Protocol |
In vivo animal studies for Licoisoflavone A would employ xenograft mouse models using colorectal cancer cell lines. The compound would be administered orally to the mice, and tumor growth inhibition would be measured.
|
| ADME/Pharmacokinetics |
Licoisoflavone A has a molecular weight of 354.35 g/mol and a molecular formula of C₂₀H₁₈O₆. It has a purity of ≥98% and should be stored at 2-8°C for up to 24 months. It is an isoflavone that is practically insoluble in water (0.015 g/L). Detailed pharmacokinetic parameters have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Licoisoflavone A has not been fully characterized. As a natural compound, it is generally considered to have low toxicity. However, its potent anti-proliferative and pro-apoptotic activities suggest it should be used with caution.
|
| References |
|
| Additional Infomation |
Licoisoflavone A belongs to the 7-hydroxyisoflavone class of compounds. It is a compound in which hydroxyl groups are substituted at the 5', 2', and 4' positions, and an isopentenyl group is substituted at the 3' position. It is a metabolite. Licoisoflavone A has been reported to be found in licorice (Glycyrrhiza uralensis), coarse licorice (Glycyrrhiza aspera), and other organisms with relevant data. See also: Glycyrrhiza glabra (partial).
Licoisoflavone A is an orally active isoflavone from licorice root with potent anti-cancer activity against colorectal cancer cells. It inhibits proliferation, induces apoptosis, and causes G1/S phase arrest. Not approved for clinical use. |
| Molecular Formula |
C20H18O6
|
|---|---|
| Molecular Weight |
354.35332
|
| Exact Mass |
354.11
|
| CAS # |
66056-19-7
|
| Related CAS # |
(S)-Licoisoflavone A; 164163-92-2
|
| PubChem CID |
5281789
|
| Appearance |
Light yellow to yellow solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
635.7±55.0 °C at 760 mmHg
|
| Flash Point |
230.9±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.690
|
| LogP |
5.08
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
593
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=CCc1c(ccc(c1O)c2coc3cc(cc(c3c2=O)O)O)O)C
|
| InChi Key |
KCUZCRLRQVRBBV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H18O6/c1-10(2)3-4-13-15(22)6-5-12(19(13)24)14-9-26-17-8-11(21)7-16(23)18(17)20(14)25/h3,5-9,21-24H,4H2,1-2H3
|
| Chemical Name |
3-[2,4-dihydroxy-3-(3-methylbut-2-enyl)phenyl]-5,7-dihydroxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~282.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8221 mL | 14.1103 mL | 28.2207 mL | |
| 5 mM | 0.5644 mL | 2.8221 mL | 5.6441 mL | |
| 10 mM | 0.2822 mL | 1.4110 mL | 2.8221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
